Medical Oncology Vol. I
Two topics, 38 cases — choose one below to browse its cases.
HER2-targeted therapy de-escalation and escalation using APT, APHINITY, and KATHERINE's own eligibility language, monarchE adjuvant CDK4/6 selection at the label's edge, extended aromatase-inhibitor therapy against bone and cardiovascular toxicity, male breast cancer endocrine pharmacology, and treatment timing in pregnancy-associated disease
Colorectal biomarker-driven sequencing (BRAF, HER2, KRAS G12C, MSI-H, sidedness), adjuvant-duration and trial-population edge cases across colon and rectal cancer, hepatobiliary and pancreatic regimen tradeoffs under organ-function and bleeding-risk constraints, and neuroendocrine and appendiceal disease decisions with no dedicated trial base of their own